



OPEN ACCESS

EDITED AND REVIEWED BY
Shoib Sarwar Siddiqui,
University of Hertfordshire, United Kingdom

*CORRESPONDENCE

Tamilanban Thamaraiyani,
✉ tamilant@srmist.edu.in
Gobinath Ramachawolran,
✉ r.gobinath@rcsiucc.edu.my
Mahendran Sekar,
✉ mahendran.sekar@monash.edu
Ling Shing Wong,
✉ lingshing.wong@newinti.edu.my

RECEIVED 24 November 2023

ACCEPTED 08 January 2024

PUBLISHED 17 January 2024

CITATION

Velayutham NK, Thamaraiyani T, Wahab S, Khalid M, Ramachawolran G, Abullais SS, Wong LS, Sekar M, Gan SH, Ebenezer AJ, Ravikumar M, Subramaniyan V, Izzati Mat Rani NN, Wu YS and Jeyabalan S (2024), Corrigendum: Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy. *Front. Pharmacol.* 15:1343756. doi: 10.3389/fphar.2024.1343756

COPYRIGHT

© 2024 Velayutham, Thamaraiyani, Wahab, Khalid, Ramachawolran, Abullais, Wong, Sekar, Gan, Ebenezer, Ravikumar, Subramaniyan, Izzati Mat Rani, Wu and Jeyabalan. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy

Naveen Kumar Velayutham¹, Tamilanban Thamaraiyani^{1*}, Shadma Wahab², Mohammad Khalid³, Gobinath Ramachawolran^{4*}, Shahabe Saquib Abullais⁵, Ling Shing Wong^{6*}, Mahendran Sekar^{7,8*}, Siew Hua Gan⁷, Angel Jemima Ebenezer⁹, Mrinalini Ravikumar¹, Vetrivelan Subramaniyan¹⁰, Nur Najihah Izzati Mat Rani¹¹, Yuan Seng Wu¹² and Srikanth Jeyabalan¹³

¹Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Chennai, Tamil Nadu, India, ²Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia, ³Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia, ⁴Department of Foundation, RCSI and UCD Malaysia Campus, George Town, Malaysia, ⁵Department of Periodontics and Community Dental Sciences, College of Dentistry, King Khalid University, Abha, Saudi Arabia, ⁶Faculty of Health and Life Sciences, INTI International University, Nilai, Malaysia, ⁷School of Pharmacy, Monash University Malaysia, Subang Jaya, Selangor, Malaysia, ⁸Center for Transdisciplinary Research, Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Science, Chennai, India, ⁹Trichy Research Institute of Biotechnology Pvt Ltd., Trichy, Tamil Nadu, India, ¹⁰Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Subang Jaya, Selangor, Malaysia, ¹¹Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh, Perak, Malaysia, ¹²Department of Biological Sciences and Centre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Subang Jaya, Selangor, Malaysia, ¹³Department of Pharmacology, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, Tamil Nadu, India

KEYWORDS

benzylisoquinoline alkaloids, stylopine, MG-63, osteosarcoma, VEGFR2

A Corrigendum on

Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy

by Velayutham NK, Thamaraiyani T, Wahab S, Khalid M, Ramachawolran G, Abullais SS, Wong LS, Sekar M, Gan SH, Ebenezer AJ, Ravikumar M, Subramaniyan V, Mat Rani NNI, Wu YS and Jeyabalan S (2023). *Front. Pharmacol.* 14:1150270. doi: 10.3389/fphar.2023.1150270

In the published article, there was an error in the **Article Title**. Instead of “*Stylopine: A potential natural metabolite to activate vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy,*” it should be “*Stylopine: A potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy.*”

Additionally, there was an error in the **Conflict of Interest** statement. The original statement omitted the declaration for commercial affiliations. The correct **Conflict of Interest** statement appears below.

Conflict of interest

Author AE was employed by Trichy Research Institute of Biotechnology Pvt Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.